Top

Published in:

01-10-2019 | Breast Cancer | Clinical trial

The relationship between ring-type dedicated breast PET and immune microenvironment in early breast cancer

Published in: Breast Cancer Research and Treatment | Issue 3/2019

Abstract

Purpose

¹⁸F-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) is related to the biological parameters and prognosis of breast cancer. However, whether whole-body PET (WBPET) and dedicated breast PET (DbPET) can reflect the tumor microenvironment is unclear. This study investigated the relationship between stromal tumor-infiltrating lymphocytes (TILs) and maximum standardized uptake value (SUVmax) in WBPET and DbPET.

Methods

A total of 125 invasive breast cancers underwent WBPET and ring-type DbPET and resected specimens were pathologically assessed. The impact of SUVmax on the tumor biological parameters and TILs was retrospectively evaluated. SUVmax was classified as high and low relative to the median values (WBPET-SUVmax: 2.2 and DbPET-SUVmax: 6.0).

Results

SUVmax correlated with tumor size, nuclear grade, Ki-67 labeling index, and TILs in both WBPET and DbPET (all p < 0.001). In multiple linear regression analysis, tumor size, Ki-67 labeling index, and TILs predicted SUVmax in WBPET and DbPET. The cutoff values of tumor size, Ki-67 labeling index, and TILs predicting high SUVmax were 20 mm, 20%, and 20%, respectively. In multivariate analysis, the predictive factors for high SUVmax were tumor size and Ki-67 labeling index for WBPET and tumor size and TILs for DbPET. High SUVmax in DbPET was related to high numbers of TILs after propensity score matching analysis; however, WBPET was not (p = 0.007 and p = 0.624, respectively).

Conclusions

Both SUVmax values in WBPET and DbPET predicted TIL concentration of the primary breast cancer. In DbPET, SUVmax represented the immune microenvironment after adjusting for tumor biological factors.

Nishikawa H, Sakaguchi S (2014) Regulatory T cells in cancer immunotherapy. Curr Opin Immunol 27:1–7. https://doi.org/10.1016/j.coi.2013.12.005 CrossRefPubMed

Stanton SE, Adams S, Disis ML (2016) Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review. JAMA Oncol 2(10):1354–1360. https://doi.org/10.1001/jamaoncol.2016.1061 CrossRefPubMed

Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, Budczies J et al (2018) Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 19(1):40–50. https://doi.org/10.1016/s1470-2045(17)30904-x CrossRefPubMed

Dieci MV, Mathieu MC, Guarneri V, Conte P, Delaloge S, Andre F, Goubar A (2015) Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Ann Oncol 26(8):1698–1704. https://doi.org/10.1093/annonc/mdv239 CrossRefPubMedPubMedCentral

Palsson-McDermott EM, O’Neill LA (2013) The Warburg effect then and now: from cancer to inflammatory diseases. BioEssays 35(11):965–973. https://doi.org/10.1002/bies.201300084 CrossRefPubMed

Lee S, Choi S, Kim SY, Yun MJ, Kim HI (2017) Potential utility of FDG PET-CT as a non-invasive tool for monitoring local immune responses. J Gastric Cancer 17(4):384–393. https://doi.org/10.5230/jgc.2017.17.e43 CrossRefPubMedPubMedCentral

Lopci E, Toschi L, Grizzi F, Rahal D, Olivari L, Castino GF, Marchetti S et al (2016) Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. Eur J Nucl Med Mol Imaging 43(11):1954–1961. https://doi.org/10.1007/s00259-016-3425-2 CrossRef

Masumoto N, Kadoya T, Sasada S, Emi A, Arihiro K, Okada M (2018) Intratumoral heterogeneity on dedicated breast positron emission tomography predicts malignancy grade of breast cancer. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-018-4791-1 CrossRefPubMed

MacDonald L, Edwards J, Lewellen T, Haseley D, Rogers J, Kinahan P (2009) Clinical imaging characteristics of the positron emission mammography camera: PEM Flex Solo II. J Nucl Med 50(10):1666–1675. https://doi.org/10.2967/jnumed.109.064345 CrossRefPubMedPubMedCentral

10.

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL et al (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784–2795. https://doi.org/10.1200/jco.2009.25.6529 CrossRefPubMedPubMedCentral

11.

Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013. https://doi.org/10.1200/jco.2013.50.9984 CrossRefPubMed

12.

Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S et al (2015) The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 26(2):259–271. https://doi.org/10.1093/annonc/mdu450 CrossRefPubMed

13.

Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48(3):452–458. https://doi.org/10.1038/bmt.2012.244 CrossRef

14.

Ohara M, Shigematsu H, Tsutani Y, Emi A, Masumoto N, Ozaki S, Kadoya T et al (2013) Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer–usefulness for malignant grade of triple-negative breast cancer. Breast (Edinburgh, Scotland) 22(5):958–963. https://doi.org/10.1016/j.breast.2013.05.003 CrossRef

15.

Kadoya T, Aogi K, Kiyoto S, Masumoto N, Sugawara Y, Okada M (2013) Role of maximum standardized uptake value in fluorodeoxyglucose positron emission tomography/computed tomography predicts malignancy grade and prognosis of operable breast cancer: a multi-institute study. Breast Cancer Res Treat 141(2):269–275. https://doi.org/10.1007/s10549-013-2687-7 CrossRefPubMedPubMedCentral

16.

Aogi K, Kadoya T, Sugawara Y, Kiyoto S, Shigematsu H, Masumoto N, Okada M (2015) Utility of (18)F FDG-PET/CT for predicting prognosis of luminal-type breast cancer. Breast Cancer Res Treat 150(1):209–217. https://doi.org/10.1007/s10549-015-3303-9 CrossRefPubMedPubMedCentral

17.

Akimoto E, Kadoya T, Kajitani K, Emi A, Shigematsu H, Ohara M, Masumoto N et al (2018) Role of (18)F-PET/CT in predicting prognosis of patients with breast cancer after neoadjuvant chemotherapy. Clin Breast Cancer 18(1):45–52. https://doi.org/10.1016/j.clbc.2017.09.006 CrossRefPubMed

18.

Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L, Ricaud M et al (2006) Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [¹⁸F]fluorodeoxyglucose positron emission tomography. J Clin Oncol 24(34):5366–5372. https://doi.org/10.1200/jco.2006.05.7406 CrossRefPubMed

19.

Sasada S, Masumoto N, Goda N, Kajitani K, Emi A, Kadoya T, Okada M (2018) Dedicated breast PET for detecting residual disease after neoadjuvant chemotherapy in operable breast cancer: a prospective cohort study. Eur J Surg Oncol 44(4):444–448. https://doi.org/10.1016/j.ejso.2018.01.014 CrossRefPubMed

20.

Fowler AM (2014) A molecular approach to breast imaging. J Nucl Med 55(2):177–180. https://doi.org/10.2967/jnumed.113.126102 CrossRefPubMed

21.

Garcia Hernandez T, Vicedo Gonzalez A, Ferrer Rebolleda J, Sanchez Jurado R, Rosello Ferrando J, Brualla Gonzalez L, Granero Cabanero D et al (2016) Performance evaluation of a high resolution dedicated breast PET scanner. Med Phys 43(5):2261. https://doi.org/10.1118/1.4945271 CrossRefPubMed

22.

Nishimatsu K, Nakamoto Y, Miyake KK, Ishimori T, Kanao S, Toi M, Togashi K (2017) Higher breast cancer conspicuity on dbPET compared to WB-PET/CT. Eur J Radiol 90:138–145. https://doi.org/10.1016/j.ejrad.2017.02.046 CrossRefPubMed

23.

Iima M, Nakamoto Y, Kanao S, Sugie T, Ueno T, Kawada M, Mikami Y et al (2012) Clinical performance of 2 dedicated PET scanners for breast imaging: initial evaluation. J Nucl Med 53(10):1534–1542. https://doi.org/10.2967/jnumed.111.100958 CrossRefPubMed

Title: The relationship between ring-type dedicated breast PET and immune microenvironment in early breast cancer
Publication date: 01-10-2019
Keywords: Breast Cancer
Breast Cancer
Positron Emission Tomography
Published in: Breast Cancer Research and Treatment / Issue 3/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-019-05339-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2019

Non-contrast MRI for breast screening: preliminary study on detectability of benign and malignant lesions in women with dense breasts

Salivary metabolomics with alternative decision tree-based machine learning methods for breast cancer discrimination

Genomic comparison of paired primary breast carcinomas and lymph node macrometastases using the Oncotype DX Breast Recurrence Score® test

Social determinants of breast cancer risk, stage, and survival

Mammographic screening in male patients at high risk for breast cancer: is it worth it?

Treating HR+/HER2− breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression

Keynote webinar | Spotlight on antibody–drug conjugates in cancer